[Main Media] [Funds Focus] Bridge

Carmignac Absolute Return Europe: Letter from the Fund Managers

Published on
15 October 2024

Over the thirds quarter of 2024, Carmignac Absolute Return Europe (A EUR Acc share class) realized a negative performance of -2.19%.

Market environment

Global equity markets produced a positive return in Q3 but the headline numbers mask a very tumultuous period of volatility during the quarter driven by a series of conflicting macro forces.
After a positive start to the early part of July, a toxic combination of weaker US data and a spike in the Japanese Yen following an interest rate rise in Japan set off a spectacular chain of events in the first few days of August which forced systematic funds to unwind their highly leveraged Yen carry trade, creating a significant global equity degrossing with long positions forcibly liquidated and covering of short positions.

Japanese equities had their worst one day sell since 1987 which was followed by the biggest upside move since 2008 and this had a knock-on effect across the globe. The VIX volatility risk indicator was propelled to a level above 60, a level only seen 3 times in the last 35 years (2008 GFC & Covid sell off in March 2020).

After an aggressive sell off, markets steadily recovered as central banks pivoted in a more dovish direction with the Fed, the ECB and the Bank of England embarking on rate cuts. In addition, US economic data which had been a cause for concern showed signs of improvement which allayed fears of a US recession. This was followed in September by another material macro event in the form of an announcement of significant economic stimulus measures from the Chinese government, which catalysed a surge in Chinese equities and China exposed stocks in European markets. On the last day of the quarter alone, Chinese equities rallied 8.3% taking the main Chinese index from a 5 year low to a 1 year high. The knock-on effect in Europe was heavy selling of year-to-date winners and defensive stocks, as investors sought to reduce multiyear underweights/shorts in China exposed names. These macro forces unleashed a series of sectoral rotations with winners one month becoming the losers next month and vice versa which acted as a short circuit to fundamental stock picking. Few, if any investors around the globe, including us were positioned for this.
Over the quarter the best performing sectors in Europe were Communications, Real Estate, Industrials and Utilities while the main detractors were Technology, Consumer Staples, Energy and Healthcare.

Performance review

These macro driven rotational forces acted as a short circuit to our fundamental stock picking and in this difficult environment the fund lost around 2%, with August seeing the worst impact. Any positive returns from our defensively positioned long book were more than offset by the losses in our single stock shorts and portfolio hedges which were squeezed higher by aggressive rotational short covering.
Within the portfolio, the most positive sector returns came from Communications, Real Estate, Industrials , Financials and Utilities while the main detractors were Technology, Consumer Staples, Energy, and Healthcare.

On a stock level, the main contributors were:

Long position in Fresenius Positive numbers drives rerating
Long position in Deutsche TelekomEarnings beat and improving cash returns
Long position in National GridRecovery from sell off ahead of capital increase
Long position in NexansSignificant contract signed for underwater power cable
Long position in VonoviaAsset disposals refinance balance sheet, German real estate market bottoming

On a stock level, the main detractors were:

Long position in ASMLDisappointing order numbers and concerns over US restrictions on sales to China
Long position in Novo NordiskLong-market worried about risk of new entrants in the GLP-1 market
Long position in National SK HynixProfit taking in AI and weak macro impacting legacy business
Long position in AlphabetDisappointing numbers
Long position in STMicroelectronicsQ2 earnings below expectations

Much of the portfolio activity for Q3 was driven by risk management in what were incredibly challenging conditions for long /short investors. Whenever the portfolio is not working, we always act to reduce risk by managing down gross exposure and in this case we took our gross exposure down from 150% at the end of June to 120% at the end of July and then down to 100% in August in order to preserve capital, until such time as the macro volatility calms down and that stocks can return to a more normal behaviour and where again we feel the risk reward is compelling enough to can take advantage of opportunities created by the moves.

Our net exposure fluctuated between 10% and mid-20%s. The principal adjustments to the portfolio were tactical reductions in longs in Technology and Healthcare and profit taking in Utilities which had performed very strongly on the back of falling bond yields. Elsewhere we reduced short positions in Consumer discretionary, Industrials and Materials and added to Financials, mainly Banks and to Real Estate names which are significant beneficiaries of falling interest rates.

What is our outlook for the coming months?

As we now embrace the challenges and opportunities of the last quarter of the year, whether the FED cuts a further 50 or 75bps before the end of the year, or indeed the ECB accelerates their pace or not, it really shouldn’t matter too much as the rate cycle has inflected. However, unlike these recent weeks when markets have quickly shifted from one narrative to another, for example from ‘the Fed being behind the curve’ to ‘ a goldilocks’ scenario and back again, we should hopefully begin to see a more stable macro trend emerging. Instead, the bigger challenge for equity investors in the coming weeks will be, how to best navigate the most important quarterly reporting season of the year. Usually, at the 9-month stage is when we tend to see a much higher frequency of corporate profit warnings (or upgrades), vs any point earlier in the year. Some refer to it as ‘ the confession season’.

This is simply due to the timing of the year, by which time management teams come to realize that time is running for them to either meet or beat their full year guidance & fiscal outlook expectations. In addition, it is also the time when most sell side analysts really begin to properly adjust their growth forecasts for the coming year ahead, so lots of earnings expectation risk which should be a fertile period for long/short investing.

Even though, uncharacteristically, and unexpectedly September was a relatively strong month for equities, given the current ‘setup’, post all these rotational forces, we believe the upcoming Q3 season will be very ‘rich’ of opportunities. We can think of several sectors, whereby the top-down narrative might be in direct conflict with the short-term bottom up. For example, some Luxury stocks have seen big rallies of their lows on the back of China stimulus, but can they sustain those gains against weak Q3’s with possibly further downgrades to 25’ estimates?

Similarly, with some of the Consumer discretionary or Industrials stocks, we face the same question and challenge. Many of these names too have rebounded, particularly Miners & Industrials in Europe that are indirectly or directly linked to China. And the main question we must ask, is how much of this rebound is due to China stimulus vs expectations of lower rates and a turn of the cycle in 2025? Meanwhile, what we do know, meeting with the management teams of several of these companies during the many conferences in September, is that their messaging is at best cautious, and with very limited visibility. In some cases, the lack of visibility is also likely to be linked to the upcoming US election, where seemingly decisions on spending, capex plans etc. are put on hold until we know the outcome of who will take the White House in November. Could that result in a rush of spending, new investment plans and announcement post the election? It is possible.

Therefore, this reporting season is likely to be particularly challenging, but equally, will offer significant opportunities both for our short and long book. This is why we are deliberately running a relatively low gross exposure at around 100% currently, keeping lot of ‘dry powder’ ready to deploy once we see the initial signs to how this reporting season will emerge, sector by sector, stock by stock. We are confident that this level of flexibility will give us the best chance to really capture as much as possible in what tends to be the best period of the whole year for alpha.

On a sector level, we stick with most of our defensive, structural Technology and Communication names, such as Meta, Amazon, Google, Microsoft & SAP. However, our weightings in more cyclical Technology names (semis) have been reduced overall and is currently mainly focused in semi equipment names, such as ASML and ASM International. Further, we’ve just recently sold our long in Nvidia post the rally in the shares but retain upside in the name through call options.

In Healthcare, a sector which has been a drag on our returns during Q2, we’ve reduced our exposures in the GLP1 names, both Novo Nordisk and Zealand. These stocks have clearly been used to fund sector rotation, and whilst we still believe in the long-term narrative for these names, it has become abundantly clear, that they now need new positive catalysts to again begin to perform. Thus, we believe Q3’s will be a big test for them, alongside new drug read outs. But with Novo having sold off by some -25% from its peaks, we do believe expectations are now possibly too low and that the stock should soon inflect. Our largest healthcare stock is today Fresenius SE which we believe is defensive and still much too cheap (11x PE).

Meanwhile, for many of the more cyclical sectors, Consumer discretionary, Industrials, Miners & Chemicals, we are today more balanced than at any time earlier in the year. This is mainly because several of our short positions in these sectors have now played out, and we subsequently taken profits. Or in some cases, it is because we simply don’t yet know what level of patience the market will ‘display’ between wanting to buy these names into a recovery next year vs likely poor Q3’s, with further FY24 downgrades?

Also is worth noting that our overall non-EU exposure is limited to ca 15% of our total gross exposure.

Finally, we continue to be net long of financials, mainly European Banks. Recent meetings with management teams of these Banks and speaking to analysts, have increased our conviction in them, despite in some cases already strong year-to-date performances. In addition, we believe that for European banks, Q3 earnings risk is relatively low vs most other European sectors. We continue to argue that due to their strong capital bases, hedged net interest incomes exposures, rich cash distribution, low valuations and more recently the emergence of European banks M&A, selective banks stocks still offer good upside from here.

Carmignac Absolute Return Europe

An opportunistic and style agnostic long/short approach to European equitiesDiscover the fund page

Carmignac Absolute Return Europe A EUR Acc

ISIN: FR0010149179
Recommended minimum investment horizon
3 years
Risk indicator*
3/7
SFDR - Fund Classification**
Article 8

*Risk Scale from the KID (Key Information Document). Risk 1 does not mean a risk-free investment. This indicator may change over time. **The Sustainable Finance Disclosure Regulation (SFDR) 2019/2088 is a European regulation that requires asset managers to classify their funds as either 'Article 8' funds, which promote environmental and social characteristics, 'Article 9' funds, which make sustainable investments with measurable objectives, or 'Article 6' funds, which do not necessarily have a sustainability objective. For more information please refer to https://eur-lex.europa.eu/eli/reg/2019/2088/oj.

Main risks of the fund

Risk associated with the Long/Short Strategy: This risk is linked to long and/or short positions designed to adjust net market exposure. The Fund may suffer high losses if its long and short positions undergo simultaneous unfavourable development in opposite directions.Equity: The Fund may be affected by stock price variations, the scale of which is dependent on external factors, stock trading volumes or market capitalization.Interest Rate: Interest rate risk results in a decline in the net asset value in the event of changes in interest rates.Currency: Currency risk is linked to exposure to a currency other than the Fund’s valuation currency, either through direct investment or the use of forward financial instruments.
The Fund presents a risk of loss of capital.

Fees

ISIN: FR0010149179
Entry costs
4,00% of the amount you pay in when entering this investment. This is the most you will be charged. Carmignac Gestion doesn't charge any entry fee. The person selling you the product will inform you of the actual charge.
Exit costs
We do not charge an exit fee for this product.
Management fees and other administrative or operating costs
2,30% of the value of your investment per year. This estimate is based on actual costs over the past year.
Performance fees
20,00% max. of the outperformance if the performance is positive and the net asset value exceeds the high-water mark. The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years, or since the product creation if it is less than 5 years.
Transaction Cost
0,98% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the investments underlying the product. The actual amount varies depending on the quantity we buy and sell.

Performance

ISIN: FR0010149179
Carmignac Absolute Return Europe2.5-8.08.914.64.4-1.35.212.6-6.40.0
Carmignac Absolute Return Europe- 1.1 %+ 3.9 %+ 3.2 %

Source: Carmignac at 30 Sep 2024.
​Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor).

Related articles

Alternative Strategy18 March 2024English

Our Merger Arbitrage strategies win ‘Best new launch’ award

1 minute(s) read
Find out more
Alternative Strategy11 March 2024English

Best ESG Alternative Fund award goes to Carmignac

1 minute(s) read
Find out more
Alternative Strategy6 September 2023English

M&A Arbitrage: A key strategy in a high interest rate environment

Speakers : Fabienne Cretin-Fumeron
Find out more

Marketing communication. Please refer to the KID/KIID, prospectus of the fund before making any final investment decisions. This document is intended for professional clients.

This material may not be reproduced, in whole or in part, without prior authorisation from the Management Company. This material does not constitute a subscription offer, nor does it constitute investment advice. This material is not intended to provide, and should not be relied on for, accounting, legal or tax advice. This material has been provided to you for informational purposes only and may not be relied upon by you in evaluating the merits of investing in any securities or interests referred to herein or for any other purposes. The information contained in this material may be partial information and may be modified without prior notice. They are expressed as of the date of writing and are derived from proprietary and non-proprietary sources deemed by Carmignac to be reliable, are not necessarily all-inclusive and are not guaranteed as to accuracy. As such, no warranty of accuracy or reliability is given and no responsibility arising in any other way for errors and omissions (including responsibility to any person by reason of negligence) is accepted by Carmignac, its officers, employees or agents.

Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.

Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice. The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.

Morningstar Rating™ : © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Access to the Funds may be subject to restrictions regarding certain persons or countries. This material is not directed to any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the material or availability of this material is prohibited. Persons in respect of whom such prohibitions apply must not access this material. Taxation depends on the situation of the individual. The Funds are not registered for retail distribution in Asia, in Japan, in North America, nor are they registered in South America. Carmignac Funds are registered in Singapore as restricted foreign scheme (for professional clients only). The Funds have not been registered under the US Securities Act of 1933. The Funds may not be offered or sold, directly or indirectly, for the benefit or on behalf of a «U.S. person», according to the definition of the US Regulation S and FATCA.
The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital.

The Funds’ prospectus, KIDs, NAVs and annual reports are available at www.carmignac.com, or upon request to the Management Carmignac Portfolio refers to the sub-funds of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive. The French investment funds (fonds communs de placement or FCP) are common funds in contractual form conforming to the UCITS or AIFM Directive under French law.

  • In France, Luxembourg, Sweden: The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital. The Funds’ prospectus, KIDs, NAV and annual reports are available at www.carmignac.com, or upon request to the Management.

  • In the United Kingdom: the Funds’ respective prospectuses, KIIDs and annual reports are available at www.carmignac.co.uk, or upon request to the Management Company, or for the French Funds, at the offices of the Facilities Agent at BNP PARIBAS SECURITIES SERVICES, operating through its branch in London: 55 Moorgate, London EC2R. This document was prepared by Carmignac Gestion, Carmignac Gestion Luxembourg or Carmignac UK Ltd. FP Carmignac ICVC (the “Company”) is an Investment Company with variable capital incorporated in England and Wales under registered number 839620 and is authorised by the FCA with effect from 4 April 2019 and launched on 15 May 2019. FundRock Partners Limited is the Authorised Corporate Director (the “ACD”) of the Company and is authorised and regulated by the FCA. Registered Office: Hamilton Centre, Rodney Way, Chelmsford, Essex, CM1 3BY, UK; Registered in England and Wales with number 4162989. Carmignac Gestion Luxembourg SA has been appointed as the Investment Manager and distributor in respect of the Company. Carmignac UK Ltd (Registered in England and Wales with number 14162894) has been appointed as a sub-Investment Manager of the Company and is authorised and regulated by the Financial Conduct Authority with FRN:984288.

  • In Switzerland: the prospectus, KIDs and annual report are available at www.carmignac.ch, or through our representative in Switzerland, CACEIS (Switzerland), S.A., Route de Signy 35, CH-1260 Nyon. The paying agent is CACEIS Bank, Montrouge, Nyon Branch / Switzerland, Route de Signy 35, 1260 Nyon.

The Management Company can cease promotion in your country anytime.
Investors have access to a summary of their rights in English on the following links: UK ; Switzerland ; France ; Luxembourg ; Sweden.